An interventional study of venographic occlusion of spermatic veins in Prostate Cancer, sponsored by Maaynei Hayesha Medical Center. Completed at 1 site in Israel. Open to male participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2008-03-17.
Sponsored by Maaynei Hayesha Medical Center · Not applicable, Interventional, and Treatment
Patients with varicocele in whon early prostate cancer will be found will undergo venographic embolization of both spermatic veins. The study hypothesis is that this procedure will induce a gradual regression of the prostate volume that may decrease prostate cancer cells. Close follow-up will ensure that necessary therapy will be provided if needed according to clinical criteria. Results in terms of prostate size PSA level and tumor size will be recorded.
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.
This study's enrollment of 10 is below the median of 58 across 4,822 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Maaynei Hayesha Medical Center is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Procedure: venographic occlusion of spermatic veins
Watch-full follow-up
Through the femoral vein a catheter is inserted into the spermatic veins in succession and the veins are occluded.
Safety performance of the procedure. The change in tumor size and prostate cancer cells as evaluated by trans-rectal ultrasound and prostate biopsy
Time frame: one year
The change in size of the prostate as evaluated by ultrasound Change in PSA value. Reduction of above 20% in nocturia
Time frame: one year
This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maaynei Hayesha Medical Center